A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Covid-19 Patients With aPH
Status:
Recruiting
Trial end date:
2021-08-15
Target enrollment:
Participant gender:
Summary
This is an open-label, multicentre study evaluating the effect, safety and tolerability of
the two regio isomers 1-(nitrosooxy)propan-2-ol and 2- (nitrosooxy)propan-1-ol (PDNO)
infusion given to COVID-19 patients with acute pulmonary hypertension (aPH).